A Cambridge biotech company using CRISPR gene editing to develop therapies for blood cancers said that its experimental treatment for acute myeloid leukemia proved safe in the first recipient, who is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback